Judge Awards Summary Judgment to Roche on Off-Label Injury Claim



DOCUMENTS
  • Order


DALLAS - FDA approval of a drug, even when prescribed for off-label use, precludes state law claims for failure to warn where there is no evidence rebutting the presumption that the drug's warnings were adequate, a judge has ruled. Holland v. Hoffman-La Roche Inc., No. 06-1298 (N.D. Texas).

Awarding summary judgment Nov. 15 to Hoffman-La Roche Inc., Judge Jeff Kaplan of the U.S. District Court for the Northern District of Texas dismissed with prejudice a case brought by a plaintiff who claimed he developed a severe eye infection and sepsis as a result of taking the company's CellCept drug.

Rickey …






UPCOMING CONFERENCES




HarrisMartin's New Jersey Asbestos Litigation Conference

March 03, 2023 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS



HarrisMartin's MDL Conference: Managing Mass Torts, Status of Key Litigations and Lessons Learned

March 29, 2023 - Tucson, AZ
Hotel Details in Tucson, Arizona, to be Announced

MORE DETAILS